Rivastigmine for Alzheimer's disease

“Mini-mental state”

1975 • 82,784 citations

Clinical diagnosis of Alzheimer's disease

1984 • 27,279 citations

ECDEU Assessment Manual for Psychopharmacology

1976 • 8,729 citations

Validity of the Trail Making Test as an Indicator of Organic Brain Damage

1958 • 7,146 citations

The Neuropsychiatric Inventory

1994 • 7,026 citations

Empirical Evidence of Bias

1995 • 5,260 citations

The Global Deterioration Scale for assessment of primary degenerative dementia

1982 • 4,700 citations

A new rating scale for Alzheimer's disease

1984 • 3,948 citations

An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease

1997 • 1,088 citations

Bias in Treatment Assignment in Controlled Clinical Trials

1983 • 889 citations

Donepezil for dementia due to Alzheimer's disease

2003 • 500 citations

A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease

1998 • 473 citations

Severe Impairment Battery

1994 • 317 citations

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer's disease

1998 • 313 citations

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:

2003 • 303 citations

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

2005 • 297 citations

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

2005 • 227 citations

Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease

2000 • 213 citations

Behavioral symptoms in mild cognitive impairment

2004 • 209 citations

Measurement of quality-of-life changes in patients with Alzheimer's disease.

1989 • 186 citations

Assessment of the severely impaired patient: Description and validation of a new neuropsychological test battery.

1990 • 184 citations

Rivastigmine

1998 • 179 citations

An efficacy and safety analysis of Exelon^® in Alzheimer’s disease patients with concurrent vascular risk factors

2000 • 158 citations

A MULTINATIONAL, RANDOMISED, 12‐WEEK, COMPARATIVE STUDY OF DONEPEZIL AND RIVASTIGMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

2002 • 158 citations

Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease

2001 • 156 citations

Rivastigmine for Alzheimer's disease

2000 • 152 citations

Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease

2004 • 127 citations

Fuld Object-Memory Evaluation

1977 • 124 citations

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease

2009 • 120 citations

Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil

2002 • 116 citations

A review of rivastigmine: A reversible cholinesterase inhibitor

2003 • 113 citations

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

1999 • 104 citations

A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®)

1999 • 102 citations

Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression

2001 • 98 citations

Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications

2000 • 91 citations

Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years

2005 • 90 citations

Donepezil, Rivastigmine, and Vitamin E in Alzheimer Disease: A Combined P300 Event-related Potentials/Neuropsychologic Evaluation over 6 Months

2001 • 82 citations

CLINICAL AND COST-EFFECTIVENESS OF DONEPEZIL, RIVASTIGMINE, AND GALANTAMINE FOR ALZHEIMER'S DISEASE

2002 • 75 citations

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

1996 • 74 citations

Preferential Cerebrospinal Fluid Acetylcholinesterase Inhibition by Rivastigmine in Humans

1999 • 72 citations

Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial

2003 • 72 citations

Short-term Effects of Acetylcholinesterase Inhibitor Treatment on EEG and Memory Performance in Alzheimer Patients: an Open, Controlled Trial

2003 • 70 citations

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease

2004 • 66 citations

Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type

1998 • 65 citations

Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine

2000 • 65 citations

A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease

2004 • 62 citations

Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients

2004 • 57 citations

Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer???s Type

2002 • 54 citations

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

2004 • 53 citations

A pilot, randomized, open‐label trial assessing safety and pharmakokinetic parameters of co‐administration of rivastigmine with risperidone in dementia patients with behavioral disturbances

2002 • 45 citations

Electrocardiographic Effects of Rivastigmine

2002 • 45 citations

Impact of Rivastigmine on Costs and on Time Spent in Caregiving for Families of Patients With Alzheimer's Disease

2003 • 40 citations

RIVASTIGMINE IN PATIENTS WITH ALZHEIMER'S DISEASE AND CONCURRENT HYPERTENSION

2002 • 37 citations

POTENTIAL LONG‐TERM EFFECTS OF RIVASTIGMINE ON DISEASE PROGRESSION MAY BE LINKED TO DRUG EFFECTS ON VASCULAR CHANGES IN ALZHEIMER BRAINS

2003 • 32 citations

The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias

2004 • 30 citations

Rivastigmine in outpatient services: experience of 114 neurologists in Austria

2002 • 23 citations

Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents

2001 • 22 citations

Rivastigmine in Alzheimer Disease: Efficacy Over Two Years

2004 • 21 citations

An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.

2002 • 18 citations

Rivastigmine was effective and safe in Alzheimer disease

1999 • 5 citations

The treatment by using rivastigmine for patients with Alzheimer disease: results of a multicenter,randomized,open-labeled,controlled clinical trial

2001 • 5 citations

529. Pharmacokinetics of rivastigmine and its metabolite in patients with Alzheimer’s disease

2000 • 4 citations

Efficacy of rivastigmine in treating mild to severe Alzheimer’s disease with different Hachinski ischemia index

2003 • 4 citations

P1-026 Consistent long-term efficacy of rivastigmine in mild, moderate and moderately severe Alzheimer's disease

2004 • 2 citations